A Phase I, Open Label, Multicenter, Dose-escalation Study of HDM201 in Adult Patients With Advanced Solid and Hematological Tumors Characterized by Wild-type TP53
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs HDM 201 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 12 Sep 2017 Planned number of patients changed from 205 to 225.
- 18 May 2017 Planned primary completion date changed from 30 Apr 2017 to 31 Jul 2017.
- 17 Mar 2017 Planned End Date changed from 5 Nov 2017 to 14 Jul 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History